MedTrace Logo

BMAC Enhanced Coronary Artery Bypass Grafting (CABG)

NCT01061580 · Status: TERMINATED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2014-06-26

No results posted yet for this study

Summary

Injection of concentrated bone marrow cells into the myocardium during CABG procedure.

Conditions

  • Congestive Heart Failure

Interventions

DEVICE

Harvest SmartPReP2 BMAC System

Injection of 10, 15, or 20 cc of BMAC

Sponsors & Collaborators

  • Harvest Technologies

    lead INDUSTRY

Principal Investigators

  • Naresh Trehan, MD · Medanta-The Medicity

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-05-31
Primary Completion
2012-12-31
Completion
2013-12-31

Countries

  • India

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01061580 on ClinicalTrials.gov